Publication:
Antiglutamatergic therapy in Alzheimer's disease - effects of lamotrigine - Short communication

Simple item page
dc.contributor.authorTANRIDAĞ, TÜLİN
dc.contributor.authorsTekin, S; Aykut-Bingol, C; Tanridag, T; Aktan, S
dc.date.accessioned2022-03-12T15:58:09Z
dc.date.accessioned2026-01-10T20:25:36Z
dc.date.available2022-03-12T15:58:09Z
dc.date.issued1998
dc.description.abstractIt has been proposed that excitotoxic damage by glutamatergic hyperactivity is responsible for neurodegeneration in Alzheimer's disease. Lamotrigine (LTG) inhibits presynaptic glutamate release and is considered to be effective in treatment of other neurodegenerative disorders by its cerebroprotective properties. We used LTG in 11 patients with the diagnosis of probable Alzheimer's disease. 300 mg/day administration of LTG improved word recognition, naming and depressed mood on Alzheimer Disease Assessment Scale (ADAS).
dc.identifier.doi10.1007/s007020050059
dc.identifier.issn0300-9564
dc.identifier.pubmed9660108
dc.identifier.urihttps://hdl.handle.net/11424/223956
dc.identifier.wosWOS:000073648600018
dc.language.isoeng
dc.publisherSPRINGER-VERLAG WIEN
dc.relation.ispartofJOURNAL OF NEURAL TRANSMISSION
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectlamotrigine
dc.subjectglutamate
dc.subjectglutamate release
dc.subjectexcitatory neurotransmitter
dc.subjectAlzheimer's disease
dc.subjectneuroprotection
dc.subjecttherapy
dc.subjectGLUTAMATE
dc.subjectDEMENTIA
dc.subjectCORTEX
dc.subjectSCALE
dc.titleAntiglutamatergic therapy in Alzheimer's disease - effects of lamotrigine - Short communication
dc.typeconferenceObject
dspace.entity.typePublication
oaire.citation.endPage303
oaire.citation.issue2-3
oaire.citation.startPage295
oaire.citation.titleJOURNAL OF NEURAL TRANSMISSION
oaire.citation.volume105

Files

Collections

Araştırma Çıktıları